Biotech and pharma deals in 2020 soared to an all-time high of 1,154 signed deals with $146.3 billion in total value, defying expectations that the global Covid-19 pandemic would hamper dealmaking. Global healthcare and life sciences R&D partnership activity was up 23 percent over 2019 and total deal values rose 31 percent from the previous year, driven in part by advances in technological and molecular understandings of disease pathways, and a drive toward targeted precision medicines.
We tapped the DealForma database to look at biopharma partnering activity in 2020 in more detail.
The Takeaways – Biopharma Deals in 2020:
- Big Pharma and Big Biotech continued to dominate the top dealmakers lists, but several mid-stage players joined the top 20 lists, including Incyte, CSL Behring, and Daiichi Sankyo for total upfront payouts, Neurocrine for total value, and Sarepta for total number of deals.
- Total upfront cash & equity was up 16.8 percent, but average upfront cash and equity fell slightly, down 3 percent compared to 2019.
- With 276 R&D partnerships focused on Covid-19, the number of infectious disease partnerships skyrocketed 572 percent over 2019, but total values of these deals fell 40 percent, even as the total paid in upfront cash and equity soared 130 percent compared to 2019.
- Biopharma mergers and acquisitions were active as well. Check out our analysis of 2020 biotech and pharma M&A here.
Biotech and Pharma Deal Terms
Biopharma R&D partnering median upfront cash and equity paid at signing soared 50 percent in 2020 compared to 2019, but average deal values dropped 3 percent during the same period.
Deals Go Earlier and Larger
Total upfront cash and equity, at $17.4 billion, rose 17 percent for biotech and pharma deals in 2020 compared to 2019. While this looks good on the surface, the money paid at signing accounted for only 11.9 percent of total potential deal values in 2020, compared to 13.4 percent of total potential deal values in 2019. So, while the numbers and potential values were strong, deals were more back-loaded with total potential deal values contingent on the achievement of milestones as licensees made riskier bets on novel platforms where they have more say on targets of interest, and early stage assets where the licensees have more control on development.
It is interesting to note that median upfront cash and equity for platform deals jumped 95 percent in 2020 compared to 2019, while it fell 33 percent for preclinical assets. Mid- and late-stage assets also commanded a premium with median upfront cash and equity up 50 percent for mid-stage asset and late-stage deals, compared to 2019.
Cancer Remains Leading Deal Target
Biotech and pharma deals in 2020 saw 379 partnerships for cancer as the top therapeutic target for dealmaking, accounting for 38.9 percent of all deals, 55 percent of total deal values, and 57.1 percent of total upfront cash and equity. We have covered this before in detail, and DealForma database users can quickly grab the latest numbers.
Neurology / CNS Deals
Indeed, 8 out of the top 12 deals in 2020 by total deal value focused on cancer as the primary therapeutic area, while 3 focused on neurologic conditions, a fast growing area of unmet need. Total deal values of neurologic partnerships made up 18.7 percent of total deal values in 2020, up 119 percent compared to 2019, with total upfront cash and equity also up 147 percent compared to 2019, in an area that has had its share of failures but that is beginning to hold promise for success with recent advances in technological innovation.
Top Biopharma Deals in 2020 by Upfront Cash & Equity
| Licensor | Licensee | Stage at Signing | Therapeutic Area | Technology | Total Deal Value ($M) | Upfront Cash & Equity ($M) |
| Seagen | Merck | Phase II | Cancer | Antibody Conjugate | 4200 | 1600 |
| Sage Therapeutics | Biogen | Phase III | Neurologic | Small Molecule | 3125 | 1525 |
| Denali Therapeutics | Biogen | Phase I | Neurologic | Small Molecule | 2150 | 1025 |
| Daiichi Sankyo | AstraZeneca | Phase I | Cancer | Antibody Conjugate | 6000 | 1000 |
| MorphoSys | Incyte | Phase III | Cancer | Antibody | 2000 | 900 |
| Blueprint Medicines | Roche | Phase I | Cancer | Small Molecule | 1702 | 775 |
| Genmab | AbbVie | Phase I | Cancer | Antibody | 3900 | 750 |
| Vaccibody | Genentech (Roche) | Phase I | Cancer | Vaccine | 1230 | 515 |
| Dragonfly Therapeutics | Bristol Myers Squibb | Phase I | Cancer | Immunotherapy | 475 | 475 |
| uniQure | CSL Behring | Phase III | Hematologic | Gene Therapy | 2050 | 450 |
| Arcus Biosciences | Gilead Sciences | Phase II | Cancer | Immunotherapy | 2000 | 375 |
| Sangamo Therapeutics | Biogen | Preclinical | Neurologic | Gene Editing/CRISPR | 2720 | 350 |
Want data for your analysis? Want us to do it? Subscribers get both.
Schedule your demo of the DealForma database to see how we help you get better reports done faster.
28,664
Deal Profiles
18,893
Funding Rounds
32,123
Company Profiles
22,077
Product Profiles
119K+
Clinical Trials
3,967
Business Developers
Specifically for Biotech, Pharma, Device, and Diagnostics
Looking Ahead
There’s every reason to think 2021 will match 2020 numbers for biopharma R&D dealmaking. A strong pace in the first half of the first quarter of 2021 has seen 132 announced collaborations with total deal values of $18.8 billion. The success of virtual partnering last year will only accelerate opportunities to partner in the years ahead with a new crop of recently launched companies in with exciting new technologies and promises of tackling once intractable diseases.
This article is a sample from the DealForma Quarterly Deal Trends Report provided to database customers. Data for this analysis was compiled using the DealForma biopharma deals database. We applied initial filters for partnerships and deal subtypes, therapeutic areas, modalities, asset stages at signing, and deal payment terms. From there, we exported the data to Excel and used pivot tables and charts to do the rest. All data are based on publicly disclosed figures. We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
Marie Daghlian is a freelance writer and editor who reports on the business of biotechnology and healthcare technologies and on rare diseases for Global Gene’s Rare Daily. She also covers the industry for Big4Bio, a daily newsletter focused on the four major biotech centers in the United States.
Chris Dokomajilar is the Founder / CEO of DealForma and has been an industry analyst for over a decade. He analyzed the data and produced the charts for this article. More about Chris.
More Research by DealForma
November 2022 Top Biopharma Deal: POINT – Lantheus for cancer drugs PNT2002 and PNT2003
The top deal upfront for Nov 2022 was the POINT – Lantheus exclusive, worldwide ex-Asia license to co-develop and commercialize POINT’s PNT2002, a PSMA-targeted 177 Lu-based radiopharmaceutical therapy, and PNT2003, a somatostatin receptor (SSTR) targeted radioligand therapy by combining POINT’s radioligand development expertise with Lantheus’ commercial expertise in PSMA PET and radiopharmaceuticals for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Additionally, POINT will be responsible for the funding, development, and manufacturing of PNT2002 and PNT2003 while Lantheus will be responsible for NDA approval and development and commercial expenses. POINT will receive $250M (for PNT2002)and $10M (for PNT2003) up front and is eligible for up to $281M and $34.5M in development milestones and up to $1.28B and $275M in commercial milestones, plus 20% and 15% royalties for PNT2002 and PNT2003, respectively.
October 2022 Top Biopharma Deal: MacroGenics – Gilead for blood cancer drug MGD024
The top deal upfront for Oct 2022 was the MacroGenics research partnership with Gilead with an option to license MGD024. MacroGenics signed a research partnership with Gilead to develop MGD024, a bispecific antibody, and two additional bispecific therapies using MacroGenics’ DART platform with an exclusive, worldwide option to license MGD024 for the treatment of certain blood cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MacroGenics will be responsible for Phase I clinical trials of MGD024 as a monotherapy and combination therapy for multiple indications. Gilead may exercise its option at predetermined decision points. MacroGenics will receive $60M in cash up front and is eligible for up to $1.7B in development, regulatory, and commercial milestones, and undusclosed option exercise fees, plus tiered, double-digit royalties for MGD024 and a flat royalty for two other therapies.
September 2022 Top Biopharma Deal: SpringWorks – GSK for Nirogacestat in combination with Blenrep
The top deal upfront for Sep 2022 was the SpringWorks expanded clinical collaboration with GSK for Nirogacestat in combination with GSK’s Blenrep. SpringWorks granted GSK non-exclusive rights to develop and commericalize Nirogacetat,an oral gamma-secretase inhibitor, in combination with GSK’s Blenrep, an antibody-drug conjugate targeting B-cell maturation antigen for the treatment of multiple myeloma. SpringWorks will receive a $75M equity investment in shares of common stock at a premium to the 30-day volume-weighted average share price on Sept 2, 2022, and is eligible to receive up to $550M in development and commercial milestones.
August 2022 Top Biopharma Deal: Sanofi – Innovent for Cancer Drugs SAR408701 and SAR444245
The top deal upfront for Aug 2022 was the Sanofi development and commercialization deal with Innovent for SAR408701 and SAR444245. Sanofi granted Innovent exclusive rights to develop and commercialize its SAR408701 (tusamitamab ravtansine) for the treatment of non-small cell lung cancer (NSCLC) and gastric cancer in China. Additionally, Sanofi and Innovent will co-develop SAR444245 for the treatment of multiple cancer drugs. Sanofi will invest EUR300M (approx. $306.6M) in Innovent up front at HK$42.42 (approx. $5.40) per share in Innovent common stock. Sanofi is eligible for EUR80M (approx. $81.7M) in development milestones plus royalties for SAR408701, while Innovent is eligible to receive EUR60M (approx. $61.3M) in development milestones and royalties for SAR444245.
July 2022 Top Biopharma Deal: Orion – MSD for Prostate Cancer Drug ODM-208
The top deal upfront for July 2022 was the Orion co-development and co-commercialization deal with MSD for ODM-208. Orion granted MSD rights to co-develop and co-commercialize ODM-208 for the treatment of metastatic castration-resistant prostate cancer. Orion and MSD have an option to convert the co-development and co-commercialization agreement into a global exclusive license to MSD. Upon exercising the option, MSD will retain the responsibility for all accrued and future development and commercialization expenses associated with the program. Orion will receive $290M up front, including $221M recognized as income, and approximately $60.3M reserved to cover Orion’s share of ODM-208 future development cost. Orion is eligible for undisclosed development and commercialization milestones, plus double-digit tiered royalties.
June 2022 Top Biopharma Deal: Sanofi – Regeneron Pharmaceuticals for Cancer/Inflammation drug Libayo
The top deal upfront for June 2022 was the Sanofi development and commercialization deal with Regeneron for Libtayo (Amended Agreement). Sanofi granted Regeneron exclusive, worldwide rights to develop and commercialize Libtayo for the treatment of cancer. Regeneron and Sanofi signed a license agreement in 2015 to develop Libtayo. Sanofi will receive $900M up front and is eligible to receive up to a $100M milestone upon the first approval by either the FDA or EMA for Libtayo in combination with chemotherapy for first-line treatment of certain patients with NSCLC and up to $100M as a sales milestone in the next two years, plus 11% royalties.
May 2022 Top Biopharma Deal: Dragonfly Therapeutics – Gilead Sciences NK cell engager for cancer/inflammation
The top deal upfront for May 2022 was the Dragonfly Therapeutics development and commercialization deal with Gilead Sciences for solid tumors. Gilead has an exclusive, worldwide option to develop and commercialize additional NK cell engager programs by using its Tri-specific NK Engager (TriNKET) platform after the completion of certain preclinical activities. Dragonfly will receive $300M up front and is eligible to receive undisclosed opt-in payments and development, regulatory, and commercial milestones, plus up to 20% royalties.
April 2022 Top Biopharma Deal: Harbour BioMed – AstraZeneca Bispecific Antibody for Cancer Treatment
The top deal upfront for April 2022 was the Harbour BioMed development and commercialization deal with AstraZeneca for solid tumors. AstraZeneca will be responsible for all costs for development and commercialization. HBM will receive $25M up front and is eligible for up to $325M in development, regulatory, and commercial milestones, plus undisclosed tiered royalties.
March 2022 Top Biopharma Deal: IGM Biosciences – Sanofi IgM Antibody Platform for Cancer and Immunology/Inflammation
The top deal upfront for March 2022 was the IGM development and commercialization deal with Sanofi for cancer, immunology, and inflammation. IGM will receive $150M up front and is eligible to receive up to $6.015B in regulatory and commercial milestones, which includes $940M for each of 3 cancer targets and $1.065B for each of 3 immunology/inflammation targets. Additionally, Sanofi has expressed an interest in purchasing up to $100M of IGM non-voting common stock in a public financing.
February 2022 Top Biopharma Deal: Heidelberg – Huadong ATAC Candidates for Cancer Treatment
The top deal upfront for February 2022 was the Heidelberg development and commercialization partnership with Huadong for HDP-101, HDP-103, and options for HDP-102 (CD37-ATAC) and HDP-104. Heidelberg will receive $20M up front and is eligible for up to $449M in milestones with additional $461M in option payments upon exercise. Additionally, Huadong will invest EUR 105M (35%) in Heidelberg, with an initial commitment of EUR 80M by purchasing 12,408,649 shares at EUR 6.44 per share.
You met on Zoom. Now it's Deal Time.
With thousands of company profiles and a decade of deals specifically in biopharma and medtech, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.